Cell and Gene Manufacturing and Logistics

31. 5 Common Pitfalls In CGT Facility Design Planning And Implementation 6/15/2026

    With shifting needs and requirements in advanced therapy manufacturing, embedding infrastructure flexibility is vital. Discover how to balance these variables for long-term success.

32. CRISPR Reagents Enable High Efficiencies Of Editing And HDR In iPSCs 6/15/2026

    Achieving consistent Homology Directed Repair (HDR) in iPSCs requires optimized CRISPR design and workflows. See how advanced reagents and targeted enhancement strategies improve insertion efficiency.

33. Collaborative Supply Chain Management In A Fragmented World 6/15/2026

    Biopharma supply chains are under pressure. As regionalization accelerates, success depends on agility, trust, and new approaches to collaboration that can withstand ongoing global uncertainty.

34. Scalable rAAV9 Production Using Advanced Cell Lines And Bioreactors 6/15/2026

    Progress in gene therapy manufacturing is being driven by improved cell line performance and scalable bioprocessing. See how high-density growth helps streamline development to larger-scale production.

35. In Vivo Gene Editing Is Moving From Promise To Proof 6/15/2026

    CGT is shifting from technical promise to clinical execution as in vivo approaches reach an inflection point where delivery, durability, specificity, and manufacturability will determine whether the field can turn breakthrough science into safe, scalable, repeatable therapies.

36. Why Cost-Sensitive Innovation Is Underrated In Development 6/12/2026

    Gain insight into how strategic decisions around equipment are enabling teams to manage complexity, improve scalability, and advance therapies without compromising financial sustainability.

37. Leveraging Integrated Media Services For Speed And Efficiency 6/12/2026

    Uncertainty in media stability can limit efficiency and scalability in biologics manufacturing. See how a data-driven approach enables more predictable planning and reduces operational strain.

38. How Equipment Choices Can Help Determine The Pace Of Drug Development 6/12/2026

    The speed of drug development depends as much on equipment choices as scientific expertise. See how flexible, integrated tools reduce delays, improve data quality, and enable faster decisions.

39. Enabling Clinical-Grade Automated Manufacturing Of γδ T Cells 6/12/2026

    Explore smarter approaches to γδ T cell manufacturing, including scalable expansion, efficient transduction, and streamlined analytics, as well as how to build workflows that support validation.

40. Establishing The First Chinese Haplobank Of Clinical-Grade hiPSCs 6/11/2026

    Learn how automated, closed workflows and GMP-ready infrastructure are advancing pluripotent stem cell development from scalable expansion and differentiation to building regional capacity.